The methylation of CpG islands in the promoters is associated with loss of protein via repression of gene transcription. Several studies have demonstrated that tumour suppressor and DNA repair genes are often aberrantly hypermethylated in colorectal cancer. The present study was conducted to examine whether the methylation profile of p16INK4a and hMLH1 (human mutL homologue 1) promoters was associated with clinical features and patients' survival in CRC (colorectal carcinoma). Aberrant methylation of p16INK4a and hMLH1 promoters was found in 47.2 and 53.4 % of tumours respectively. For adjacent non-tumoral mucosa, p16INK4a was fully unmethylated in 30 % of the cases, whereas hMLH1 was predominantly unmethylated (76 %). Methylation of p16INK4a correlated with gender and tumour size (P = 0.005 and 0.035 respectively), whereas those of hMLH1 significantly correlated with overall survival (P log rank = 0.007). Concomitant methylation of p16INK4a and hMLH1 was associated with TNM (tumour, lymph node and metastases) stage and tumour size (P = 0.024 and 0.021 respectively). Our data show that loss of hMLH1 expression through aberrant methylation could be used as a marker of poor prognosis in CRC.
INTRODUCTION
CRC (colorectal cancer) remains the most prevalent gastrointestinal cancer all over the world [1] . The incidence of CRC in Tunisia was in the range of 2.5-4.5 per 100 000 in 2002 [2] . In colorectal carcinogenesis, the progressive accumulation of genetic and epigenetic alterations contributes to malignant transformation of normal colonic mucosa into cancer [3, 4] . Chromosomal and MSI (microsatellite instability) pathways constitute the major genetic instability events in colorectal cancer [4, 5] . Hypermethylation of gene promoter regions is often observed in colorectal cancer and contributes to the silencing of a number of genes, including tumour suppressor genes, e.g. p16INK4a, hMLH1 [human MLH1 (mutL homologue 1)], MGMT (methylguanine-DNA methyltransferase) and APC (adenomatous polyposis coli) [6] [7] [8] . In recent years, the role of this silencing mechanism in the aetiology
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of colorectal cancer has increasingly been recognized. Toyota et al. [6] originally proposed that a subset of sporadic colorectal cancers displays a promoter CpG island methylator phenotype.
In the present study, we focused on two selected genes (those encoding p16INK4a and hMLH1) on the basis of their key cellular functions and involvement in carcinogenesis including CRC. P16INK4a is a CDK4 (cyclin-dependent kinase 4) inhibitor that specifically acts at the G 1 /S phase of the cell cycle by negatively controlling the Rb (retinoblastoma) phosphorylation status [9] . The methylation of p16INK4a has been reported to occur at a frequency of 7-53 % in malignant colorectal tumours [10] [11] [12] [13] . Other reports implicated p16INK4a methylation as being an early event during colorectal carcinogenesis, whereas others suggest that it is a late event [14] [15] [16] .
In addition, epigenetic alterations affect genes that are critical to the maintenance of DNA stability, such as that encoding hMLH1 [17] . Approx. 15 % of all colorectal cancers show a high level of MSI, reflecting dysfunction of the post-replicative DNA mismatch repair system, mainly through the CpG methylationmediated silencing of the hMLH1 gene [18, 19] . The present study was conducted with the aim of studying the methylation frequency of p16INK4a and hMLH1 gene promoters in sporadic CRC of Tunisian patients and to investigate whether the methylation profile correlated with clinical behaviour and prognosis.
MATERIALS AND METHODS

Patient characteristics
A total of 72 primary sporadic adenocarcinomas were collected between January 2003 and December 2007 from patients who underwent radical surgical resection at the Department of Digestive Surgery of Habib Bourguiba University Hospital (Sfax, Tunisia). All patients gave informed consent prior to specimen collection according to institutional guidelines. None of the patients had preoperative or postoperative chemotherapy. Tissues were also taken from the neighbouring non-cancerous mucosa (at least 5-10 cm away from the tumorous lesions) of 20 patients. At the time of surgery, the age of patients ranged from 25 to 85 years (mean: 62.9 years) and the sex ratio was 1.5 . The histological subtypes were classified using the WHO (World Health Organization) criteria [20] . The carcinomas were staged according to the TNM (tumour, lymph node and metastases) classification adopted by the American Joint Committee on Cancer [21] .
DNA extraction and MSP (methylation-specific PCR)
DNA was extracted from formalin-fixed, paraffin-embedded tissues. After tumour identification on H/E (haematoxylin and eosin)-stained slides, tumoral areas were scraped from 10-mmthick paraffin sections. The collected materials were de-waxed by washing with xylene and rinsed in ethanol. Dried tissues were digested with proteinase K in the presence of SDS at 55
• C overnight, followed by phenol/chloroform extraction as described in [22] . The quantity of DNA was checked by a spectrophotometer and stored at − 20
• C for further use. For MSP assays, DNA samples (1-2 μg) were subjected to sodium bisulfite treatment, which specifically converts the unmethylated cytosine residues into uracil using a Methyl Detector kit as recommended by Active Motif. The bisulfite-treated DNA was then amplified using specific primers for methylated and unmethylated alleles as described in [23] . The sequences of the primers, annealing temperature and product size are listed in Table 1 . PCRs were performed in 25 μl containing 0.2 μM of each primer pair, 200 μM dNTP, 2 mM MgCl 2 , 1× PCR buffer and 1 unit of Taq DNA polymerase (Fermentas). Amplification was carried out in a thermal cycler (Applied Biosystems) with initial denaturation at 95
• C for 10 min, followed by 35 cycles (30 s at 95
• C, 30 s at optimal temperature and 45 s at 72
• C) and a final cycle of 10 min extension at 72 • C. Fully methylated DNA (provided by Active Motif) and lymphocyte DNA from healthy individuals were used as positive controls for the methylated and unmethylated reactions respectively. A blank control without DNA was included in each PCR assay. The PCR products were electrophoresed on a 2.5 % agarose gel and visualized under UV illumination after ethidium bromide staining.
MSI analysis
Genomic DNA extracted from normal and tumour tissue samples was amplified by PCR at the five-microsatellite Bethesda panel (D2S123, D5S346, D17S250, BAT26 and BAT25).
PCRs were performed in a total volume of 25 μl containing 1 × buffer, 0.125 mM deoxynucleoside triphosphate, 0.2 μM of each primer and 0.25 unit of Taq DNA polymerase (Fermentas). The PCR conditions were described previously [24] . After PCR, 2 μl of the product was mixed with 8 μl of loading buffer containing formamide and Rox size standards. This mixture was denatured at 95
• C for 2 min and cooled on ice before loading on to an ABI PRISM 3100 sequencer (Applied Biosystems). The results were analysed using GeneScan software (Applied Biosystems).
The tumours were classified into the following [25] : MSI-H (high degree of MSI) if two or more of the five markers showed
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BRAF (encoding B-Raf kinase) V600E mutation detection
To determine the BRAF V600E mutations, exon 15 of the BRAF gene was amplified using the forward primer 5 -TCATAATGCTTGCTCTGATAGGA-3 and the reverse primer 5 -CTTTCTAGTAACTCAGCAGC-3V. Amplifications were carried out using Taq DNA polymerase (Fermentas) and a PCR profile consisting of a 10 min initial denaturation at 95
• C followed by 40 cycles of 20 s at 94
• C, 20 s at 60
• C and 30 s at 72
• C with a 10 min final extension at 72
• C. Mutations were verified by sequencing.
RNA extraction and RT-PCR (reverse transcription-PCR)
Total RNA was isolated from fresh frozen tissues with TRIzol ® according to the manufacturer's protocol (Invitrogen). Firststrand cDNA synthesis was performed on total RNA, previously treated with DNase I (Amersham Biosciences), using 2 μg of RNA, 0.5 μg of oligo(dT), 2 mM dNTP, 0.5 unit/μl RNase inhibitor (Amersham Biosciences), 4 μl of 5 × RT buffer and 200 units of MMLV (Moloney-murine-leukaemia virus) reverse transcriptase (Invitrogen). The reaction mixture was incubated at 37
• C for 1 h, followed by 70
• C for 10 min. cDNA (3 μl) was used as a template in PCR using specific primers for p16INK4a, forward: 5 -GGGGGCACCAGAGGCAGT-3 , reverse: 5 -GGTTGTGGCGGGGGCAGTT-3 (160 bp); and hMLH1, forward: 5 -GTGCTG GCAATCAAGGGACCC-3 , reverse 5 -CACGGTTGAGGCATTGGGTAG-3 (214 bp) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as an endogenous control: forward, 5 -ACCCACTCCTCCACCTTT-3 and 5 -ACCCACTCCTCCACCTTTG-3 (188 bp). After 5 min of initial denaturation, 35 cycles of 94
• C for 45 s, 58
• C for 45 s and 72
• C for 1 min were performed. The PCR products were analysed on a 2 % agarose gel, stained with ethidium bromide and visualized under UV light.
Statistical analysis
Statistical analyses were performed using SPSS 13.0 statistical software for Windows. The two-sided χ 2 test or Fisher's exact test was used to determine associations between the methylation status of p16INK4a and hMLH1 with various clinico-pathological features. Correlation with overall survival was performed using the Kaplan-Meier survival plots and the significance was tested using the log-rank test. The Cox proportional hazards model was used for multivariate analysis of prognostic factors. P < 0.05 was considered statistically significant.
RESULTS
Methylation profiles of p16INK4a and hMLH1 gene promoters
To investigate the epigenetic changes in p16INK4a and hMLH1, we analysed by MSP the promoter methylation status in 72 CRC specimens and 20 normal adjacent mucosae. Figure 1 shows representative examples of MSP results. It is worth noting that, in some samples, we observed both the methylated and unmethylated bands. This profile, termed 'hemimethylated', could be explained either by (i) the presence of non-malignant cells in addition to the tumour cells in the biopsies or (ii) cellular heterogeneity within the same tumour knowing that DNA methylation is a progressive process during carcinogenesis. The p16INK4a and hMLH1 gene promoters were methylated in 47.2 and 53.4 % of the cases respectively. In contrast, in normal adjacent mucosa, 14 out of 20 specimens displayed the hemimethylated pattern and six samples were totally unmethylated for p16INK4a, whereas hMLH1 was predominantly unmethylated (13 out of 20 cases). These data suggest that methylation of p16INK4a occurs early during CRC carcinogenesis.
Association between methylation and clinicopathological features Table 2 summarizes the association between the methylation status of p16INK4a and hMLH1 and clinico-pathological features. The most consistent association was found between p16INK4a methylation and gender with a significant higher frequency of methylation in women compared with men (69 % versus 34 %, P = 0.005, Table 2 ). In addition, a correlation was found with tumour size (P = 0.035, Table 2 ). Aberrant methylation of hMLH1 was more often observed in rectosigmoide than in colon and rectum, but the difference was not significant statistically (P = 0.063, Table 2 ). Among the 72 CRC specimens, 18 (25 %) are methylated in both promoters, whereas 18 specimens are totally unmethylated and 36 tumours exhibit the hemimethylated pattern. Concomitant methylation of p16INK4a and hMLH1 correlated with TNM and tumour size (P = 0.024 and 0.021 respectively, Table 2 ).
Association of p16INK4a and hMLH1 methylation with patients' survival
The survival rate was available for only 38 patients and the followup time ranged from 0.5 to 72 months. As shown in Figure 2 , patients with the methylated p16INK4a gene promoter have a slightly prolonged survival rate when compared with those with unmethylated profile (P log rank = 0.185, Figure 2A ), whereas the Kaplan-Meier analysis shows that the methylation status of hMLH1 is predictive of poor survival. Indeed, patients with the unmethylated hMLH1 gene promoter have a significantly prolonged survival rate when compared with those with a methylated profile (P log rank = 0.007, Figure 2B ), suggesting that it could be an important prognostic factor of CRC; nevertheless, this finding should be confirmed on larger series. Furthermore, in the multivariate analysis, factors such as age, gender, tumour size, lymph node metastasis and methylation profile of p16INK4a and hMLH1 were included in the Cox proportional hazards model. The results indicated that, in addition to tumour size, the methylation of hMLH1 was an independent prognostic factor ( Table 3) .
Relationship between p16INK4a and hMLH1 expressions with the methylation profile
In attempt to validate the effect of aberrant methylation on the expressions of p16INK4a and hMLH1, we performed RT-PCR analysis on 20 available fresh frozen tumours with methylated, unmethymated or hemimethylated profiles using GAPDH as the Figure 3 Representative results of MSP and RT-PCR for p16INK4a (A) and hMLH1 (B) in primary CRC GAPDH was used as an endogenous control. Abbreviation: T, tumour tissues. Samples T7, T8 and T9, unmethylated; T6, methylated; and T5, T10 and T11, hemimethylated. Lanes U and M correspond to unmethylated and methylated DNAs respectively. H 2 O, negative control for MSP; L, 100 bp DNA ladder (Fermentas).
control gene (Figure 3) . The association between promoter methylation status and RT-PCR results did not reach statistical significance probably because of the small number of cases. However, we showed that the two tumours with the p16INK4a methylated DNA failed to express the corresponding mRNA, whereas this transcript was detected in six out of seven cases with the unmethylated pattern. For the samples with partial methylation, the p16INK4a mRNA was detected in seven out of 11 cases, suggesting that the methylation at the CpG islands in the p16INK4a promoter is responsible, at least in part, for the loss of mRNA expression ( Figure 3A) . On the other hand, among the 20 samples tested, the five tumours displaying the unmethylated hMLH1 DNA did not express the transcript, whereas the hMLH1 mRNA was observed in 12 out of 15 cases in tumours with hemimethylated profile ( Figure 3B ).
BRAF mutation and MSI status
BRAF V600E mutation was detected in five out of 66 specimens (7.5 %). No association was found between BRAF mutation and aberrant methylation of individual gene promoters. However, concomitant methylation of p16INK4a and hMLH1 is likely to be more prevalent in tumours harbouring the V600E mutation (40 % versus 24.6 %), but statistical significance was not reached ( Table 2) . MSI analysis was carried out on 41 tumours; among them 14 (35.7 %) were MSI-H and 27 (48.1 %) were MSS. No association was found between the MSI status and aberrant methylation of p16INK4a and hMLH1; however, hypermethylation of hMLH1 was more often observed in MSI-H tumours (Table 2) .
On the other hand, we assessed the influence of MSI on patients' survival and found that, compared with patients with MSS tumours, those with MSI-H tumours have a shorter survival rate as shown in Figure 2 (C).
DISCUSSION
Aberrant methylation of CpG islands in gene promoters is a frequent event in cancer, and it can affect critical steps in the process of carcinogenesis such as DNA repair and cell cycle control [8, 26, 27] . In the present study, aberrant methylation of p16INK4a and hMLH1 gene promoters was found in 47.2 and 53.4 % of tumours respectively. In CRC, the methylation status of p16INK4a and hMLH1 gene promoters has been extensively studied and the percentage of aberrant methylation varies widely from one study to another [28] [29] [30] . Methodological differences may be one explanation for such variability, but it could also be attributed to ethnic variations caused by genetic and/or dietary factors. To the best of our knowledge, this is the first report on p16INK4a and hMLH1 methylation profile in Tunisian patients with CRC and their correlation with major clinical features and survival. In the present study, we showed that methylation of p16INK4a correlated with gender and tumour size (P = 0.005 and 0.035 respectively). Other authors have found that p16INK4a methylation correlated with mucinous histology, more advanced T stage, lymph node involvement and poor prognosis [13, 16, 31] . methylation and any of the clinical features except for a tendency of association with tumour location (P = 0.063), which is in line with a previous report showing that methylation of hMLH1 is more often seen in proximal than in distal tumours [32] . The correlation between p16INK4a hypermethylation and prognosis in patients with CRC is controversial [33] [34] [35] [36] [37] . In the present study, the Kaplan-Meier plot showed that patients with methylated p16INK4a promoter have a slightly more prolonged overall survival rate than those exhibiting unmethylated DNA (P log rank = 0.185). In contrast, methylation of hMLH1 correlated significantly with overall survival since patients with unmethylated hMLH1 gene promoter have a significant prolonged survival rate compared with those with the methylated profile (P log rank = 0.007), suggesting that it could be an important prognostic factor of CRC. The Cox regression model revealed that in addition to tumour size, the methylation of hMLH1 could have a prognostic value; nevertheless, this finding should be confirmed since the follow-up data were available for only 38 among 72 patients included in the present study.
In summary, our results show that, in sporadic colorectal cancers, methylation of p16INK4 is frequently involved in gene silencing. Furthermore, methylation of hMLH1 strongly correlated with shortened patients' survival. These observations have an important impact on the therapy of colorectal cancer, since drug resistance can be mediated by loss of mismatch repair, and recovering such a key function by the action of demethylated agents might lead to the overcoming of the drug resistance effect.
B-Raf is related to the Ras/Raf/MEK [MAPK (mitogenactivated protein kinase)/extracellular-signal-regulated kinase kinase]/MAPK signal transduction pathway, and oncogenic mutations in BRAF, mainly the V600E mutation, have been reported in colon cancer [38, 39] . Previous studies suggested that BRAF mutation is closely associated with sporadic MSI-positive CRCs, but recent data indicate that BRAF mutation is associated with CIMP (CpG island methylator phenotype) rather than MSI [40] [41] [42] . The present study supports somehow the association of BRAF mutation with promoter methylation, because the BRAF mutation rate is slightly higher in tumours exhibiting concomitant methylation of p16INK4a and hMLH1.
The prognostics implications of the MSI status were investigated in CRC patients. Ogino et al. [42] showed that patients with MSS tumours experienced a significant reduction in colon cancer-specific mortality when compared with those with MSI-H tumours. It was also reported that the MSI-negative subtype associated with CIMP-positive showed worse clinical outcome [43] . In contrast, we showed that patients with MSS tumours had better prognosis than those with MSI-H tumour; however, due to the limited number of patients, these data should be confirmed in further studies.
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